Hedge funds raced to cover their Treasury short positions ahead of the release of inflation data for December as speculation mounted about a looming recession and a slow down in rate hikes, according to a report by Bloomberg.
Activist investor Chris Hohn’s TCI Fund made its first loss in 13 years in 2022 with the fund ending the year 18% down as Stockmarket prices tumbled during a widespread sell-off in growth stocks, according to a report by Bloomberg.
Ken Griffin’s Citadel is now the best ever performing hedge fund in terms of annual returns having chalked up a $16 billion profit for investors in 2022 on the back of a raft of winning wagers including bonds and equities,
Cleavemoor, a consumer sector investment advisor, has launched Cleavemoor 10, a new open ended hybrid vehicle employing the firm’s proprietary Agile Horizon Strategy, which combines a consumer sector long/short public equities portfolio with longer-term consumer private equity investments.
Crossover hedge funds that invest in fast-growing public and private companies may have lost tens of billions of clients’ money last year, but that hasn’t deterred some managers from planning to bring more of them to market in the coming
Oil trader Pierre Andurand’s main Andurand Commodities Discretionary Enhanced hedge fund was down 19% last week as oil prices fell below $74 a barrel in New York on the back of global recession fears, according to a report by Bloomberg.
DE Shaw’s flagship hedge fund, the DE Shaw Composite Fund, weathered last year’s high-volatility environment to chalk up gains of 24.7% after fees, ahead of average annual hedge fund industry returns, according to a report by Reuters. The report cites
SurgoCap Partners, a new hedge fund founded by Maia Gaonkar, started trading on Tuesday with $1.8 billion under management, making it the largest ever debut of a female-led hedge fund, according to a report by Bloomberg.
Catalio Capital Management, a multi-strategy life sciences investment firm with more than $1 billion in assets under management, has launched a dedicated public equities hedge fund investment strategy focused on identifying compelling life science investment opportunities globally.Â
Investment manager Neal Berger’s Contrarian Macro Fund chalked up gains of 163% last year on the back of a series of successful bets that US Federal Reserve rate hikes would cause market turmoil, according to a report by Bloomberg. The
